Recent News

• 12.01.2025 - NeurAxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access to More Patients with Functional Abdominal Pain
• 11.12.2025 - NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives
• 11.11.2025 - NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues
• 11.04.2025 - NeurAxis to Host Third Quarter 2025 Results and Business Update Call on Tuesday, November 11, 2025
• 10.24.2025 - NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population
• 09.18.2025 - NeurAxis to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Recent Filings

• 11.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.10.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.24.2025 - 8-K Current report
• 10.23.2025 - 8-K Current report
• 10.23.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 10.09.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 10.08.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 09.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.10.2025 - 4 Statement of changes in beneficial ownership of securities